Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population

References

• Lip GY, Fauchier L, Freedman SB, et al. Atrial fibrillation. Nat Rev Dis Primers. 2016;2:16016.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Atrial fibrillation. [cited 2020 Sep 11]. Available from: https://www.cdc.gov/heartdisease/atrial_fibrillation.htm.
   Google Scholar
• Lip GY, Banerjee A, Lagrenade I, et al. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol. 2012;5(5):941–948.
   PubMed Web of Science ®Google Scholar
• Vyas V, Lambiase P. Obesity and atrial fibrillation: epidemiology, pathophysiology and novel therapeutic opportunities. Arrhythm Electrophysiol Rev. 2019;8(1):28–36.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292(20):2471–2477.
   PubMed Web of Science ®Google Scholar
• Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155(5):469–473.
   PubMedGoogle Scholar
• Khairallah F, Ezzedine R, Ganz LI, et al. Epidemiology and determinants of outcome of admissions for atrial fibrillation in the United States from 1996 to 2001. Am J Cardiol. 2004;94(4):500–504.
   PubMed Web of Science ®Google Scholar
• Lane DA, Skjoth F, Lip GYH, et al. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc. 2017;6(5):e005155.
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125.
   PubMed Web of Science ®Google Scholar
• Berkovitch A, Kivity S, Klempfner R, et al. Body mass index and the risk of new-onset atrial fibrillation in middle-aged adults. Am Heart J. 2016;173:41–48.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Botker HE, Pedersen L, et al. Comparison of the frequency of atrial fibrillation in young obese versus young nonobese men undergoing examination for fitness for military service. Am J Cardiol. 2014;113(5):822–826.
   PubMed Web of Science ®Google Scholar
• Karasoy D, Bo Jensen T, Hansen ML, et al. Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. Europace. 2013;15(6):781–786.
   PubMed Web of Science ®Google Scholar
• Tedrow UB, Conen D, Ridker PM, et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol. 2010;55(21):2319–2327.
   PubMed Web of Science ®Google Scholar
• May M, Schindler C, Engeli S. Modern pharmacological treatment of obese patients. Ther Adv Endocrinol Metab. 2020;11:2042018819897527.
   Web of Science ®Google Scholar
• Dzeshka MS, Lip GY. Non-vitamin K oral anticoagulants in atrial fibrillation: where are we now? Trends Cardiovasc Med. 2015;25(4):315–336.
   PubMed Web of Science ®Google Scholar
• Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308–1313.
   PubMed Web of Science ®Google Scholar
• Kalani C, Awudi E, Alexander T, et al. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients. Hosp Pract. 2019;47(4):181–185.
   PubMedGoogle Scholar
• Kido K, Ngorsuraches S. Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation. Ann Pharmacother. 2019;53(2):165–170.
   PubMed Web of Science ®Google Scholar
• Kushnir M, Choi Y, Eisenberg R, et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol. 2019;6(7):e359–e365.
   PubMed Web of Science ®Google Scholar
• Patil T, Lebrecht M. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. Thromb Res. 2020;192:124–130.
   PubMed Web of Science ®Google Scholar
• Peterson ED, Ashton V, Chen YW, et al. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J. 2019;212:113–119.
   PubMed Web of Science ®Google Scholar
• Perales IJ, San Agustin K, DeAngelo J, et al. Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight. Ann Pharmacother. 2020;54(4):344–350.
   PubMed Web of Science ®Google Scholar
• Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Curr Med Res Opin. 2020;36(7):1081–1088.
   PubMed Web of Science ®Google Scholar
• Sebaaly J, Kelley D. Direct oral anticoagulants in obesity: an updated literature review. Ann Pharmacother. 2020;54(11):1144–1158.
   PubMed Web of Science ®Google Scholar
• De Caterina R, Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol. 2017;106(8):565–572.
   PubMed Web of Science ®Google Scholar
• Fava JP, Starr KM, Ratz D, et al. Dosing challenges with direct oral anticoagulants in the elderly: a retrospective analysis. Ther Adv Drug Saf. 2018;9(8):405–414.
   PubMed Web of Science ®Google Scholar
• Ball J, Carrington MJ, McMurray JJ, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167(5):1807–1824.
   PubMed Web of Science ®Google Scholar
• Jackson SL, Tong X, Yin X, et al. Emergency department, hospital inpatient, and mortality burden of atrial fibrillation in the United States, 2006 to 2014. Am J Cardiol. 2017;120(11):1966–1973.
   PubMed Web of Science ®Google Scholar
• Williams BA, Chamberlain AM, Blankenship JC, et al. Trends in atrial fibrillation incidence rates within an integrated health care delivery system, 2006 to 2018. JAMA Netw Open. 2020;3(8):e2014874.
   PubMed Web of Science ®Google Scholar
• Pandey A, Gersh BJ, McGuire DK, et al. Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF Registry. JACC Clin Electrophysiol. 2016;2(3):355–363.
   PubMedGoogle Scholar
• Moore KT, Kroll D. Influences of obesity and bariatric surgery on the clinical and pharmacologic profile of rivaroxaban. Am J Med. 2017;130(9):1024–1032.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Real-world data (RWD) and real-world evidence (RWE) are playing an increasing role in health care decisions. 2020. [cited 2020 Feb 11]. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence.
   Google Scholar
• IQVIA™ Adjudicated health plan claims user guide – September 2019. https://www.iqvia.com/library/fact-sheets/iqvia-pharmetrics-plus
   Google Scholar
• Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560–566.
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228–1234.
   Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Foy AJ, Mandrola J, Liu G, et al. Relation of obesity to new-onset atrial fibrillation and atrial flutter in adults. Am J Cardiol. 2018;121(9):1072–1075.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Reaves AB, Tolley EA, et al. Comparison of initial warfarin response in obese patients versus non-obese patients. J Thromb Thrombolysis. 2013;36(1):96–101.
   PubMed Web of Science ®Google Scholar
• Martin BJ, Chen G, Graham M, et al. Coding of obesity in administrative hospital discharge abstract data: accuracy and impact for future research studies. BMC Health Serv Res. 2014;14:70.
   PubMed Web of Science ®Google Scholar
• Lloyd JT, Blackwell SA, Wei II, et al. Validity of a claims-based diagnosis of obesity among Medicare beneficiaries. Eval Health Prof. 2015;38(4):508–517.
   PubMed Web of Science ®Google Scholar
• Ammann EM, Kalsekar I, Yoo A, et al. Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data. Pharmacoepidemiol Drug Saf. 2018;27(10):1092–1100.
   PubMed Web of Science ®Google Scholar
• Jain R, Watzker A, Luo X, et al. Validation of obesity coding among newly treated nonvalvular atrial fibrillation patients using an integrated electronic medical record and claims database. Curr Med Res Opin. 2020;36(2):189–197.
   PubMed Web of Science ®Google Scholar
• Berry SD, Ngo L, Samelson EJ, et al. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc. 2010;58(4):783–787.
   PubMed Web of Science ®Google Scholar
• Abdel-Qadir H, Fang J, Lee DS, et al. Importance of considering competing risks in time-to-event analyses: application to stroke risk in a retrospective cohort study of elderly patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2018;11(7):e004580.
   PubMed Web of Science ®Google Scholar